Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of neoplastic plasma cells that usually secrete monoclonal proteins. Recent studies have shown that most, if not all ...

Multiple myeloma starts in the plasma cells inside your bone marrow. People with multiple myeloma have high levels of certain proteins in their blood and urine. An oncologist (a medical doctor ...

Medically reviewed by Lindsay Cook, PharmD Multiple myeloma (also referred to as myeloma) is a type of rare, incurable cancer of the blood—also known as hematologic cancer. It affects cells called ...

Larson and Tomlinson, 4 in investigating the relation between alterations in serum protein concentrations and antibody production, included 4 patients with multiple myeloma in the group of 12 ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

The Central Coast Myeloma Support Group (CCMSG) is continuing its quest to support cancer patients in the region. Myeloma is a specific form of cancer of ...

Response of myeloma to treatment was defined as ≥ 50% decrease of myeloma protein in the serum and ≥ 90% reduction of Bence-Jones proteinuria. Differences among various groups were compared ...

We do not know what causes MGUS. There may be a link to autoimmune diseases, genetics, or environmental factors. Like multiple myeloma, MGUS starts in a type of white blood cell called plasma cells.

Talquetamab combined with teclistamab shows a high response rate in patients with relapsed or refractory multiple myeloma, with 80% responding to the recommended phase 2 regimen.